Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

NCT06730126 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

15

Enrollment

NIH

Sponsor class

Conditions

Autoimmune Lymphoproliferative Syndrome

Interventions

DRUG: Soquelitinib

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)